These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29703264)

  • 1. Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder.
    Yamashita K; Kinoshita M; Miyamoto K; Namba A; Shimizu M; Koda T; Sugimoto T; Mori Y; Yoshioka Y; Nakatsuji Y; Kumanogoh A; Kusunoki S; Mochizuki H; Okuno T
    J Neuroinflammation; 2018 Apr; 15(1):125. PubMed ID: 29703264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
    Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
    Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial DNA enhance innate immune responses in neuromyelitis optica by monocyte recruitment and activation.
    Shimizu M; Okuno T; Kinoshita M; Sumi H; Fujimura H; Yamashita K; Sugimoto T; Sakakibara S; Sakakibara K; Koda T; Tada S; Ishikura T; Murata H; Beppu S; Shiraishi N; Sugiyama Y; Nakatsuji Y; Kumanogoh A; Mochizuki H
    Sci Rep; 2020 Aug; 10(1):13274. PubMed ID: 32764561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
    Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of inflammation in neuromyelitis optica spectrum disorders.
    Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
    Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity.
    Peng Y; Chen J; Dai Y; Jiang Y; Qiu W; Gu Y; Wang H
    Mult Scler Relat Disord; 2020 Apr; 39():101888. PubMed ID: 31869599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder.
    Wang Y; Zhou Y; Sun X; Lu T; Wei L; Fang L; Chen C; Huang Q; Hu X; Lu Z; Peng L; Qiu W
    Neuroimmunomodulation; 2016; 23(5-6):352-358. PubMed ID: 28445879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
    Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
    Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance.
    Jarius S; Franciotta D; Paul F; Ruprecht K; Bergamaschi R; Rommer PS; Reuss R; Probst C; Kristoferitsch W; Wandinger KP; Wildemann B
    J Neuroinflammation; 2010 Sep; 7():52. PubMed ID: 20825655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid Level of Soluble CD27 Is Associated with Disease Severity in Neuromyelitis Optica Spectrum Disorder.
    Liu B; Zhong X; Lu Z; Qiu W; Hu X; Wang H
    Neuroimmunomodulation; 2018; 25(4):185-192. PubMed ID: 30423585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
    J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tuller F; Holzer H; Schanda K; Aboulenein-Djamshidian F; Höftberger R; Khalil M; Seifert-Held T; Leutmezer F; Berger T; Reindl M
    J Neuroinflammation; 2016 Jul; 13(1):176. PubMed ID: 27371173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
    Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.
    Sato DK; Callegaro D; de Haidar Jorge FM; Nakashima I; Nishiyama S; Takahashi T; Simm RF; Apostolos-Pereira SL; Misu T; Steinman L; Aoki M; Fujihara K
    Ann Neurol; 2014 Aug; 76(2):305-9. PubMed ID: 24977390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Yoshikura N; Kimura A; Hayashi Y; Inuzuka T
    J Neuroimmunol; 2017 Sep; 310():150-157. PubMed ID: 28756870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Homocysteine Level Is Associated with the Expanded Disability Status Scale in Neuromyelitis Optica Spectrum Disorder.
    Liang J; Liu J; Fan R; Chen Z; Chen X; Tong J; Chen Y; Peng F; Jiang Y
    Neuroimmunomodulation; 2019; 26(5):258-264. PubMed ID: 31655825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
    Baek SH; Kim B; Shin JY; Choi SJ; Ahn SH; Choi YS; Kim SM; Sung JJ
    J Neuroimmunol; 2021 Sep; 358():577637. PubMed ID: 34229205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.